178 related articles for article (PubMed ID: 33444534)
1. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
Verma AM; Patel A; Subramanian S; Smith PJ
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534
[No Abstract] [Full Text] [Related]
2. Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
Little RD; Ward MG; Sparrow MP
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2430-2431. PubMed ID: 36155249
[No Abstract] [Full Text] [Related]
3. [Biological drugs in inflammatory bowel disease: Management and care].
Guerra I; Bermejo F
Rev Esp Enferm Dig; 2015 Jul; 107(7):454. PubMed ID: 26140643
[No Abstract] [Full Text] [Related]
4. Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic.
Suárez Ferrer C; Pérez Robles T; Martín-Arranz MD
Rev Esp Enferm Dig; 2021 Feb; 113(2):154. PubMed ID: 33371704
[TBL] [Abstract][Full Text] [Related]
5. Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study.
Buisson A; Nachury M; Pereira B; Fumery M
Clin Gastroenterol Hepatol; 2024 May; 22(5):1127-1129.e2. PubMed ID: 37802269
[TBL] [Abstract][Full Text] [Related]
6. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
Hilley P; Wong D; Ma R; Peterson A; De Cruz P
Intern Med J; 2024 Jun; 54(6):970-979. PubMed ID: 38214034
[TBL] [Abstract][Full Text] [Related]
7. Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease.
Rosh JR
Curr Gastroenterol Rep; 2008 Jun; 10(3):302-7. PubMed ID: 18625142
[TBL] [Abstract][Full Text] [Related]
8. Rapid infliximab infusions are generally well-tolerated in children with inflammatory bowel disease.
Glover C; Phuong L; Hinds R
J Paediatr Child Health; 2017 Jan; 53(1):94-95. PubMed ID: 28070959
[No Abstract] [Full Text] [Related]
9. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease.
Michielan A; Martinato M; Favarin A; Zanotto V; Caccaro R; Caruso A; Sturniolo GC; D'Incà R
Dig Liver Dis; 2015 May; 47(5):372-7. PubMed ID: 25708258
[TBL] [Abstract][Full Text] [Related]
10. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.
Adler J; Sandberg KC; Shpeen BH; Eder SJ; Dhanani M; Clark SJ; Freed GL
J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):35-8. PubMed ID: 23459317
[TBL] [Abstract][Full Text] [Related]
11. A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease.
Gupta SR; Crandall WV; Donegan A; Johnson M; Drobnic B; Oates M; Boyle B; Maltz RM; Dotson JL
J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):544-550. PubMed ID: 31219936
[TBL] [Abstract][Full Text] [Related]
12. Infliximab therapy in children and adolescents with inflammatory bowel disease.
Veres G; Baldassano RN; Mamula P
Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
[TBL] [Abstract][Full Text] [Related]
13. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
Ma D; Wong W; Aviado J; Rodriguez C; Wu H
Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
[TBL] [Abstract][Full Text] [Related]
14. Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid.
Hämäläinen A; Lahdenne P; Wikström A; Aalto K; Kolho KL
Clin Exp Rheumatol; 2012; 30(4):590-1. PubMed ID: 22766212
[No Abstract] [Full Text] [Related]
15. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
16. Letter: The feasibility and safety of accelerated infliximab infusions in patients with inflammatory bowel disease.
Nantes Ó; Rodríguez C; Basterra M; Gómez M; Cambra K; Ibáñez B; Fernandez-Urien I; Arín A
Aliment Pharmacol Ther; 2014 Feb; 39(4):444-5. PubMed ID: 24447320
[No Abstract] [Full Text] [Related]
17. Organising infusions: Application administration and complications.
Collins G
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():26. PubMed ID: 27273034
[No Abstract] [Full Text] [Related]
18. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
[TBL] [Abstract][Full Text] [Related]
19. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
Qazi T; Shah B; El-Dib M; Farraye FA
Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
[TBL] [Abstract][Full Text] [Related]
20. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
